Online marketing continues to drive Rx drug Web site traffic: study

Share this article:
Online marketing has become an increasingly important driver of consumer traffic to prescription drug Web sites, results from a recent study indicate. According to the findings of an analysis conducted in October by Internet behavior tracking firm comScore Pharmaceutical Solutions, approximately 31% of visitors first become aware of pharmaceutical Web sites or products through an online marketing program. One-fifth, or 20%, of all consumer online researchers reported they first became aware of a product via an online search, with individuals age 35-54 accounting for 23% of those visits. Other online marketing programs such as banner ads were responsible for driving 10% of all traffic, the study found. Depression was the top-ranked therapeutic area with 2.9 million unique visitors, the survey said. Bipolar disorder and insomnia ranked second and third with 1.8 million and 1.7 million unique visitors, respectively. “Key players in depression, bipolar and insomnia have invested heavily in the online channel, through banner and search campaigns,” said Carolina Petrini, VP of comScore Pharmaceutical Solutions. “Pharmaceutical companies are increasingly realizing the impact of online marketing on patients and prospects and are re-allocating their marketing funds accordingly.”
Share this article:
close

Next Article in News

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?